Creo Medical Group PLC (LON:CREO - Get Free Report) insider Richard John Rees sold 6,429 shares of the company's stock in a transaction that occurred on Tuesday, July 22nd. The shares were sold at an average price of GBX 14 ($0.19), for a total value of £900.06 ($1,209.60).
Creo Medical Group Trading Down 1.8%
Creo Medical Group stock traded down GBX 0.25 ($0.00) during mid-day trading on Friday, hitting GBX 13.75 ($0.18). The company's stock had a trading volume of 502,937 shares, compared to its average volume of 1,228,805. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96. The stock's fifty day moving average is GBX 13.52 and its two-hundred day moving average is GBX 13.90. Creo Medical Group PLC has a 1 year low of GBX 9.22 ($0.12) and a 1 year high of GBX 37 ($0.50). The firm has a market capitalization of £55.59 million, a PE ratio of -2.18 and a beta of 0.86.
Creo Medical Group (LON:CREO - Get Free Report) last released its earnings results on Monday, May 19th. The company reported GBX (8) (($0.11)) earnings per share (EPS) for the quarter. Creo Medical Group had a negative net margin of 73.93% and a negative return on equity of 41.79%. On average, analysts anticipate that Creo Medical Group PLC will post -10.0800005 EPS for the current year.
Creo Medical Group Company Profile
(
Get Free Report)
Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.
The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.
Featured Stories
Before you consider Creo Medical Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Creo Medical Group wasn't on the list.
While Creo Medical Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
